SAB Biotherapeutics (SABS)
(Delayed Data from NSDQ)
$2.23 USD
+0.04 (1.83%)
Updated Aug 7, 2025 04:00 PM ET
After-Market: $2.20 -0.03 (-1.35%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, SAB Biotherapeutics, Inc. has a market cap of $20.34M, which represents its share price of $2.19 multiplied by its outstanding shares number of 9.29M. As a small-cap company, SABS's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
SABS 2.23 +0.04(1.83%)
Will SABS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SABS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SABS
SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates
SABS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates
Other News for SABS
SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates | SABS Stock News
SAB Biotherapeutics reports Q2 EPS ($1.09) vs. (79c) last year
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
SAB Biotherapeutics (SABS) Stock Rating Maintained as Price Target Adjusted | SABS Stock News